Final programme February 20

Please click **here** for all abstracts

Sunday March 8

1500	Registration open	
1700 - 1730	**Opening Ceremony**	
1730 - 1830	**Session 1: Welcome**	**Chair: Victor Skrinska**
1730 - 1800	O1. History of Newborn Screening; Newborn Screening and Public Health Infrastructure Initiatives	Jim Bonham (UK)
1800 - 1830	O2. Newborn screening in Cyprus O3. Selective Screening for Inborn Errors of Metabolism in Cyprus	Argyris Argyriou (Cyprus) Anthi Drousiotou (Cyprus)
1830 - 2000	**Welcome reception**	

Monday March 9

0800	Registration Open	
0900 - 1100	**Session 2: Country reports**	**Chairs: Gerard Loeber/Tawfeq Ben Omran**
0900 - 1100	O4. The Status of Newborn Screening Programs In The Countries of MENA Region, Report From Country Delegates	
	Bahrain	tbc
	Egypt	Heba Khafagy
	Iran	Farzad Kobarfard
	Iraq	Roula Hamid
	Jordan	Safwan Dababneh
	Kuwait	Amir Abdelazim
	Lebanon	Issam Khneisser
	Libya	tbc

Final programme February 20

	Morocco	Layachi Chabraoui
	Oman	Fathiya Al Murshedi
	Palestine Authority	Samir Khatib
	Pakistan	Hafsa Majid
	Qatar-	Victor Skrinska
	Saudi Arabia	Ahmed Alfares
	UAE	Mohamed Salahedin Riad
	Yemen	Ahmad Alshehari
1100 - 1130	**Coffee (exact time depending on the number of country reports)**	
1130 - 1230	**Session 3: Challenges**	**Chairs: Issam Khneisser/Heba Khafagy**
1130 - 1200	O5. Experiences, Hopes, Despair and Challenges to Implement Newborn Screening Programs In The Countries of the MENA Region.	Layachi Chabraoui (Morocco)
1200 – 1230	O6. The impact of consanguinity on the incidence of inherited metabolic disorders: challenges and opportunities.	Tawfeg Ben Omran (Qatar)
1230 - 1345	**Lunch plus PerkinElmer-sponsored symposium, see invitation**	
1345 - 1555	**Session 4: Various conditions**	**Chairs: Victor Skrinska/Enzo Ranieri**
1345 – 1405	O7. Congenital hypothyroidism screening	Farzad Kobarfard (Iran)
1405 – 1420	O8. Neonatal screening for congenital hypothyroidism: Experience from Morocco	Asmae Tantane (Morocco)
1420 - 1435	O9. Determining reference ranges for tT4 in dried blood samples of newborn screenings	Ralph Fingerhut (Switzerland)
1435 - 1455	O10. Congenital Adrenal Hyperplasia Screening	Toni Torresani (Switzerland)
1455 - 1515	O11. Cystic Fibrosis Screening	Ralph Fingerhut (Switzerland)
1515 – 1535	O12. Severe Combined Immunodeficiency Screening	Ghassan Dbaibo (Lebanon)

Final programme February 20

1535 - 1555	O13. Newborn screening for SCID in the Polish-German trans-border area: experiences from the first year of collaboration.	Maria Gizewska (Poland)
1555 - 1625	**Coffee, tea**	
1625 - 1805	**Session 5: Metabolic conditions**	**Chairs: Anthi Drousiotou/Issam Khneisser**
1625 - 1645	O14. Aminoacidopathies, fatty acids and organic acid oxidation disorders screening using MS/MS, updates and new developments	Issam Khneisser (Lebanon)
1645 - 1655	O15. Phenylketonuria screening in the Republic of Kazakhstan	Alexandra Murtazaliyeva (Kazakhstan
1655 - 1705	O16. Expansion of the Dutch Newborn Screening panel: the first months of screening for CPT-I, PA, MMA	Rose Maase (Netherlands)
1705 - 1725	O17. Lysosomal storage disease screening, update and latest	Rola Mitri (Qatar)
1725 - 1735	O18. Targeted-Population Screening for Mucopolysaccharidoses. Paving the way to newborn screening	Zoltan Lukacs (Germany)
1735 - 1745	O19. Screening and diagnosis of Lysosomal Storage Disorders using a two-tier screening strategy of enzyme activity and metabolites by tandem mass spectrometry (MS/MS)	Enzo Ranieri (Australia)
1745 - 1805	O20. Advances in treatment of Genetic Disorders: Lessons learned from Neuromuscular and Lysosomal Disorders	Tawfeg Ben Omran (Qatar)
Tuesday March 10		
0800	Registration open	
0900 - 1000	**Session 6: Haemoglobinopathies and related conditions**	**Chairs: Kate Hall/Amal Saadallah**
0900 - 0920 0920 - 0940 0940 - 1000	O21. Haemoglobinopathies Screening in MENA region O22. Haemoglobinopathies Methodology O23. G6PD Screening	Mohamed Salahedin Riad (UAE) Stuart Moat (UK) Issam Khneisser (Lebanon)
1000 - 1030	**Coffee/Tea Break**	

Final programme February 20

1030 - 1150	**Session 7: Follow-up and treatment**	**Chairs: Jim Bonham/Rodney Howell**
1030 - 1050 1050 - 1110 1110 - 1130 1130 – 1145 1145 - 1200	O24. Follow-up on a positive screening result, practical issues O25. Follow-up on a positive screening result, clinical issues O26. Ethical Considerations in Newborn Screening O27. The importance of cooperation between the public and private sectors in developing countries in the field of newborn screening O37. Routine Newborn Screening of Newborns. Why can't ISNS & other International organisations make it mandatory in Asia? Newborn Screening: Why is Asia lagging behind & what can they do?	Victor Skrinska (Qatar) Amal Saadallah (Saudi Arabia) Ali Al Odaib (Saudi Arabia) George Sahyoun (Jordan) Kishore Kumar (India)
1200 - 1245	Meeting of the ISNS-MENA members and information on ISNS	**Chair: Jim Bonham**
1245 - 1400	**Lunch plus Bio-Rad-sponsored symposium**	
1400 - 1800	**Session 8: Workshops**	**Chairs: Jim Bonham, Gerard Loeber**
1400 - 1530 (Parallel Session)	Group 1: Participants from countries with existing National NBS Programme • Choosing conditions for inclusion in a newborn blood spot program • Managing a co-ordinated programme by the use of links to birth registers, KPIs and following up incidents. • The need to ensure blood spot quality • The practice of EQA and IQ • The importance of second tier testing • The benefit of gaining outcomes to help assess the effectiveness of screening • Maintaining confidentiality and public confidence in screening	Moderators: Jim Bonham, Marleen Jansen, Christine Cavanagh, Stuart Moat, Kostas Petritis, Enzo Ranieri, Rose Maase, Rachel Knowles
	Group 2: Participants from countries without National NBS programme • NBS: A Primary Health Care Program • How to start? Forming a multidisciplinary group • Registering birth – old ways and new ways • Involving/engaging parents with NBS • Taking samples and transport to laboratory • Paying for programme	Moderators: Gerard Loeber, Kate Hall, Ghassan Abdoh, Victor Skrinska, Maria Gizewska

Final programme February 20

	• Deciding which conditions to include • Laboratory Infrastructure, Requirements and Instrumentations • Quality Considerations • Laboratory Accreditation • Confirmatory diagnostics • Involving/engaging Clinical professionals • Information to parents • Nutritional Interventions • Involvement of ISNS	
1530 - 1600	**Coffee, tea**	
1600 - 1730 (Parallel Session)	Group 1: Participants from those countries with National NBS Programme (continued) Group 2: Participants from those countries with no National NBS programme (continued)	
1730 - 1800	Plenary discussion on results of the workshops	**Chairs: Jim Bonham, Gerard Loeber**
1900 - 2200	**Conference Dinner**	
Wednesday March 11		
0800	Registration open	
0900 - 1000	**Session 9: Quality issues**	**Chairs: Rose Maase/Jamal Golbahar**
0900 - 0920	O28. Quality assurance and quality control program for first tier and second tier testing.	Kostas Petritis (USA)
0920 - 0940	O29. Advances in Molecular technology for the follow up and second tier testing.	Vasiliki Chini (Qatar)
0940 - 1000	O30. Storage and use of residual newborn screening specimens	Rachel Knowles (UK)

Final programme February 20

1000 - 1030	**Coffee Break**	
1030 - 1150	**Session 10: Miscellaneous**	**Chairs: Gerard Loeber/Rodney Howell**
1030 – 1040	O32. High incidence of congenital hypothyroidism in Pakistan calls for action: need of a national newborn screening program	Hafsa Majid (Pakistan)
1040 – 1055	O33. A comprehensive evaluation of the Hellenic newborn screening: new people, new technologies, new possibilities	Dimitrios Platis (Greece)
1055 – 1115	O34. PKU patients born before the era of population newborn screening: is it still possible to improve their life quality?	Maria Gizewska (Poland)
1115 – 1130	O35. IT infrastructure for screening, diagnosis and long-term follow-up for newborn screening in Sweden	Lene Sörensen (Sweden)
1130 – 1150	O36. The use of 2nd tier blood-spot metabolites by Tandem Mass Spectrometry (MS/MS) to reduce the false positive rate on routine Newborn Screening for Inborn Errors of Metabolism (IEM).	Enzo Ranieri (Australia)
1150 - 1215	General Discussion and Wrap up	**Chair: Jim Bonham**
1215	**Closure**	Victor Skrinska

Poster presentations

P1. *Combined effect of gestational age and birth weight on metabolites related to inherited metabolic diseases in neonates*
Ling Wang, Fang Yi, Chengdu Newgenegle Clinical Laboratory, Clinical department, Chengdu, China, People's Republic

P2. Should genetic markers be nominated for the new expanded NBS panel?
Adel Zeglam, Samira Tarhooni, Tripoli University Hospital, Pediatrics, Tripoli, Libya

Final programme February 20

P3. Newborn Screening for G6PD Deficiency and the Mutational Spectrum in Vietnam
Quoc Hai Luyen, Bionet Vietnam, Newborn screening center, Ha Noi, 10000, Vietnam

P4. 14 Years experience in expanding Newborn Screening using MSMS and confirmation positive results in KFSHRC ,Saudi Arabia
Mohamed S Alamoodi, KFSHRC, Genetic, Riyadh, Saudi Arabia

P5. Development of a HILIC-LC-MS analytical method to screen pyridoxine dependent epilepsy from dried blood spot
Sudheer Moorkoth, Elizabeth Mary Mathew, Leslie Lewis, Pragna Rao, Manipal College of Pharmaceutical Sciences, Pharmaceutical Quality Assurance, Manipal, India

P6. An innovative SMA screening method directly from dried blood spots
Charlotte Vandermeulen, Axel Giltay, Liselot Detemmerman, LaCAR MDx, Molecular diagnostic, 4102 Liège, Belgium

P7. Development and validation of a spatially multiplexed digital microfluidics platform to screen for Biotinidase deficiency and galactosemia
Sandeep Kalelkar, Candice Brannen, Jon Washburn, Hari Patel, Anirudh Ullal, Sally Chopra, David Billings, Daniel Mun, Baebies, Newborn Screening, Durham, United States

P8. Determination of multplex enzyme assay activities in DBS samples using NeoLSD KIT and LC-MS/MS.
Najah Obeidat, Esraa Okour, Jordan university of science and technology, Princess Haya Biotechnology Center, Irbid-Jordan, Jordan

P9. Quantitation of glycosaminoglycans in amniotic fluid by liquid chromatography tandem mass spectrometry: a potential tool for the rapid prenatal identification of MPS in pregnancies at risk
Francyne Kubaski, Rejane G. Kessler, Andryele Z. Machado, Inamara S. Moraes, Fernanda Medeiros, Fernanda Bender, Maira G. Burin, Kristiane Michelin-Tirelli, Dafne D.G. Horovitz, Anelise Barth, Robert W. Mason, Shunji Tomatsu, Roberto Giugliani, UFRGS/HCPA/INGAMEP, PPGBM, Porto Alegre, Brazil

P10. Biochemical and molecular characterization of CTNS mutations in Tunisian patients with cystinosis
Rouaida Gafsi, Latifa Chkioua, Azza Dandana, Wael Bahia, Hela Boudabous, Maroua Nouiri Bouzaabia, Maissa Brahim, Neji Tebib, Khelifa Limem, Salima . Ferchichi, University of Monastir, Faculty of pharmacy, 5000 Monastir, Tunisia

P11. Profile of Mucopolysaccharidoses diagnosed at the Biochemistry laboratory in Farhat Hached Hospital – Sousse Tunisia
Wael Bahia, Azza Dandana, Zina Chamekh, Hela Boudabous, Maroua Nouiri Bouzaabia, Maissa Brahim, Neji Tebib, Khelifa Limem, Salima Ferchichi, Farhat HACHED Hospital, Laboratory of Clinical Biochemistry, Sousse, Tunisia

Final programme February 20

P12. The Metachromatic Leucodystrophy: Experience of laboratory of clinical Biochemistry In Farhat HACHED Hospital
Wael Bahia, Azza Dandana, Zina Chamekh, Hela Boudabous, Maroua Nouiri Bouzaabia, Maissa Brahim, Neji Tebib, Khelifa Limem, Salima Ferchichi, Farhat HACHED Hospital, Laboratory of Clinical Biochemistry, Sousse, Tunisia

P13. Clinical, biological and molecular profiles of Fabry disease in Tunisian families: A Case Report
Latifa Chkioua, Chaima Saheli, Hela Boudabous, Lamia Jaafoura, Salima Ferchichi, Neji Tebib, Sandrine Laradi, University of Monastir, Faculty of pharmacy, 5000 Monastir, Tunisia

P14. *Gaucher disease in a Tunisian family*
Azza Dandana, Wael Bahia, Zina Chamekh, Hela Boudabous, Maissa Brahim, Neji Tebib, Khelifa Limem, Salima Ferchichi, Farhat HACHED Hospital, Laboratory of Clinical Biochemistry, Sousse, Tunisia

P15. *N370S (c.1226 A>G) mutation among Tunisian patients with Gaucher Disease*
Azza Dandana, Wael Bahia1, Zina Chamekh, Hela Boudabous, Maroua Nouiri Bouzaabia, Maissa Brahim, Neji Tebib, Khelifa Limem, Salima Ferchichi, Farhat HACHED Hospital, Laboratory of Clinical Biochemistry, Sousse, Tunisia